奥兰诺芬
癌症研究
免疫系统
癌细胞
药理学
程序性细胞死亡
癌症
化学
医学
细胞凋亡
免疫学
类风湿性关节炎
生物化学
内科学
作者
Mengqi Yang,Jiaxin Liu,Jianan Li,Shijun Wen,Yumin Hu,Wenhua Lu,Jinyun Liu,Peng Huang,Panpan Liu
出处
期刊:Redox biology
[Elsevier]
日期:2024-09-01
卷期号:75: 103245-103245
被引量:1
标识
DOI:10.1016/j.redox.2024.103245
摘要
Since the survival of lymphoma patients who experience disease progression or relapse remains very poor, new therapeutic approaches and effective drugs are urgently needed. Here we show that auranofin (AF), an anti-rheumatoid drug thought to inhibit thioredoxin reductases (TXNRDs) as its mechanism of action, exhibited potent activity against multiple cancer types, especially effective against B cell lymphoma. Surprisingly, a knockdown of TXNRD1 and TXNRD2 did not cause significant cytotoxicity, suggesting that abrogation of TXNRD enzyme per se was insufficient to cause cancer cell death. Further mechanistic study showed that the interaction of AF with TXNRD could convert this antioxidant enzyme to a ROS-generating molecule via disrupting its electron transport, leading to a leak of electrons that interact with molecular oxygen to form superoxide. AF also suppressed energy metabolism by inhibiting both mitochondria complex II and the glycolytic enzyme GAPDH, leading to a significant depletion of ATP and inhibition of cancer growth in vitro and in vivo. Importantly, we found that the AF-mediated ROS stress could induce PD-L1 expression, revealing an unwanted effect of AF in causing immune suppression. We further showed that a combination of AF with anti-PD-1 antibody could enhance the anticancer activity in a syngeneic immune-competent mouse B-cell lymphoma model. Our study suggests that AF could be a potential drug for lymphoma treatment, and its combination with immune checkpoint inhibitors would be a logical strategy to increase the therapeutic activity.
科研通智能强力驱动
Strongly Powered by AbleSci AI